Brokerages Set Hikma Pharmaceuticals PLC (LON:HIK) Price Target at GBX 2,038

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is GBX 2,060.

A number of research analysts have recently commented on HIK shares. Berenberg Bank increased their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday. Citigroup boosted their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Jefferies Financial Group increased their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th.

Insider Activity

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. 22.04% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Stock Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,647 on Monday. The company’s 50 day moving average price is GBX 1,547.41 and its two-hundred day moving average price is GBX 1,454.95. The firm has a market capitalization of £3.44 billion, a P/E ratio of 9.10, a P/E/G ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.